Immunocore has raised a $130 million (€117 million) series B round, ending its long wait for fresh funding. The British biotech made waves in 2015 with a $320 million series A but reportedly had to slash the near-unicorn valuation it achieved back then to get the latest round off the ground. Immunocore will use the proceeds to fund pivotal clinical studies of its metastatic uveal melanoma prospect tebentafusp, formerly known as IMCgp100, and collaborations with Genentech in MAGE-A4 and GlaxoSmithKline in NY-ESO-1. Source: Fierce Biotech 2/3/2020